LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven TumorsKelli‐Ann Monaco(Bristol-Myers Squibb (Germany)), Giordano Caponigro(Novartis (Switzerland))Clinical Cancer ResearchDecember 22, 202010.1158/1078-0432.ccr-20-2563Cited by 87SaveCiteExport RISWatch citationsRelated PapersThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity|Nature|2012|8.5kNext-generation characterization of the Cancer Cell Line Encyclopedia|Nature|2019|3.7kCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation|Nature|2010|1.4k